Uniclonal Antibody Production Services Manufacturers

All the antibodies the immune system normally produces in response to a specific antigen are capable of marking (binding to) that antigen, but these antibodies—termed polyclonal—are varied & not identical. Monoclonal antibodies (MoAbs) that share a specific antigenic target are identical and are more sensitive to that target than are polyclonal antibodies for the same antigen. MoAbs are the products of hybridomas—cells that result from the biotech fusion of bone-marrow tumor cells and B lymphocytes. Hybridomas can be geared to produce specific MoAbs continuously. Monoclonal antibodies represent a primary sector of the biopharmaceuticals market. The specificity of mAbs against antigens has tremendous clinical value, making them effective therapeutic agents. Many large-sized pharmaceutical companies are looking at mAb research more closely after the success of products, such as Remicade and Rituxan. Processes for the purification of these antibodies will have a significant impact on a company's bottom line. Monoclonal antibodies are used in many diagnostic kits as they provide the specificity, rapidity and ease required.